4.7 Review

Platinum-containing heterometallic complexes in cancer therapy: advances and perspectives

期刊

INORGANIC CHEMISTRY FRONTIERS
卷 9, 期 11, 页码 2424-2453

出版社

ROYAL SOC CHEMISTRY
DOI: 10.1039/d2qi00205a

关键词

-

资金

  1. National Natural Science Foundation of China [22077108, 21877092, 22007027]
  2. Hong Kong Research Grants Council [11304318, 11307419, 11303320, 11302221]
  3. Science Technology and Innovation Committee of Shenzhen Municipality [JCYJ20210324120004011]
  4. Natural Science Foundation of Hebei Province [B2019201465]
  5. Science Fund for Creative Research Groups of Nature Science Foundation of Hebei Province [B2021201038]
  6. Selected Returned Overseas Professionals Project of Hebei Province [C20200304]

向作者/读者索取更多资源

Platinum-based anticancer drugs face challenges such as drug resistance and toxicity. Incorporating second metal centers into platinum complexes is a promising strategy to improve their efficacy. This review focuses on Pt-containing heterometallic complexes for cancer therapy, discussing their design, anticancer activities, mechanism of action, and interplay between platinum and the second metal center.
Platinum-based anticancer drugs are among the most widely used antineoplastics in clinical settings. Their therapeutic applications and outcomes are, however, greatly hampered by drug resistance, systemic toxicity, and the lack of antimetastatic and diagnostic properties. The incorporation of second metal centers with distinct biological targets and favorable physical and chemical properties into platinum complexes is a promising strategy to improve the anticancer efficacy of platinum drugs and overcome their shortcomings. This review focuses on Pt-containing heterometallic complexes Pt-M (M = Ru, Au, Ti, Fe, Rh, Pd, Cu, Ir, Gd, Eu, Re, and Tc) for cancer therapy. The design, anticancer activities, mechanism of action, and interplay between Pt and the second metal center are discussed. Many dual-pharmacophore heterometallic complexes have shown a great potential for overcoming cisplatin resistance. Besides, the incorporation of Ru(iii) or areneRu(ii) moieties into Pt complexes has been proved to inhibit cancer metastasis effectively. Moreover, theragnostic heterometallic complexes have been obtained by combining cytotoxic Pt and luminescent Eu(iii), MRI responsive Gd(iii), or radioactive Tc-99m(i) into a single molecule. We also discuss the photophysical and bioimaging properties of theragnostic heterometallic complexes. This review provides a comprehensive landscape of representative examples of Pt-containing heterometallic complexes investigated in the last decade for cancer therapy and may guide researchers in exploring the challenges and opportunities in this emerging field.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据